Cargando…
Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698595/ https://www.ncbi.nlm.nih.gov/pubmed/34944695 http://dx.doi.org/10.3390/biomedicines9121881 |
_version_ | 1784620314725974016 |
---|---|
author | Wakade, Chandramohan Chong, Raymond Seamon, Marissa Purohit, Sharad Giri, Banabihari Morgan, John C. |
author_facet | Wakade, Chandramohan Chong, Raymond Seamon, Marissa Purohit, Sharad Giri, Banabihari Morgan, John C. |
author_sort | Wakade, Chandramohan |
collection | PubMed |
description | A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores. Secondary outcome measures were depression, sleep quality, mental flexibility and cognition, and physical fatigue. Niacin treatment was well-tolerated by forty-five subjects. The mean [95% CI] change in UPDRS III scores at six months of placebo was −0.05 [95% CI, −2.4 to 2.32], and niacin was −1.06 [95% CI, −3.68 to 1.57]. From six to twelve months when both groups received open-label niacin supplementation, the average UPDRS III scores significantly decreased for the placebo group by 4.58 [95% CI, −0.85 to 8.30] and the niacin group by 4.63 [95% CI, 1.42 to 7.83] points. Low-dose niacin supplementation is a well-tolerated adjunct therapy and may improve motor function in PD when taken over a longer period. |
format | Online Article Text |
id | pubmed-8698595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86985952021-12-24 Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial Wakade, Chandramohan Chong, Raymond Seamon, Marissa Purohit, Sharad Giri, Banabihari Morgan, John C. Biomedicines Article A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores. Secondary outcome measures were depression, sleep quality, mental flexibility and cognition, and physical fatigue. Niacin treatment was well-tolerated by forty-five subjects. The mean [95% CI] change in UPDRS III scores at six months of placebo was −0.05 [95% CI, −2.4 to 2.32], and niacin was −1.06 [95% CI, −3.68 to 1.57]. From six to twelve months when both groups received open-label niacin supplementation, the average UPDRS III scores significantly decreased for the placebo group by 4.58 [95% CI, −0.85 to 8.30] and the niacin group by 4.63 [95% CI, 1.42 to 7.83] points. Low-dose niacin supplementation is a well-tolerated adjunct therapy and may improve motor function in PD when taken over a longer period. MDPI 2021-12-10 /pmc/articles/PMC8698595/ /pubmed/34944695 http://dx.doi.org/10.3390/biomedicines9121881 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wakade, Chandramohan Chong, Raymond Seamon, Marissa Purohit, Sharad Giri, Banabihari Morgan, John C. Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial |
title | Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial |
title_full | Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial |
title_fullStr | Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial |
title_full_unstemmed | Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial |
title_short | Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial |
title_sort | low-dose niacin supplementation improves motor function in us veterans with parkinson’s disease: a single-center, randomized, placebo-controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698595/ https://www.ncbi.nlm.nih.gov/pubmed/34944695 http://dx.doi.org/10.3390/biomedicines9121881 |
work_keys_str_mv | AT wakadechandramohan lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial AT chongraymond lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial AT seamonmarissa lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial AT purohitsharad lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial AT giribanabihari lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial AT morganjohnc lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial |